Conjunctivitis is an indication for drug development with over 60 pipeline drugs currently active. According to GlobalData, preregistered drugs for Conjunctivitis have a 90.91% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Conjunctivitis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Conjunctivitis overview
Conjunctivitis, commonly known as “pink eye”, refers to inflammation of the conjunctiva, the thin, transparent layer covering the white part of the eye and the inner surface of the eyelids. This condition can be caused by various factors, including infections, allergies, or irritants. Viral conjunctivitis is typically caused by viruses associated with the common cold; it is highly contagious and often spreads through coughing, sneezing, or direct contact with infected eye secretions. It causes redness, watery eyes, and sometimes a gritty feeling. Bacterial conjunctivitis can lead to redness, swelling, a sticky discharge, and crusty eyelids, especially after sleep. It’s also contagious and can spread through direct contact. Allergic conjunctivitis is triggered by allergens such as pollen, dust, or pet dander, and can result in red, itchy, and watery eyes, and is not contagious. Irritant conjunctivitis is caused by irritants such as smoke, chemicals, or foreign objects entering the eye, leading to redness, watering, and discomfort, and is also not contagious.
For a complete picture of PTSR and LoA scores for drugs in Conjunctivitis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
